1. Automated Output Example Slides
All these slides are produced automatically for you by the PromoPlanner4
with its in-build Share Insights Reporting Feature.
Download Your Free Tool with Demo Data at

2. Input Data Summary
The following slides summarise some of the key inputs to the model.
They are an important anchor point and should be included in the output report.

3. Sales Forecast
Actual Value GBP
2018
2019
2020
2021
2022
2023
2024
2025 Σ
186,805,152
193,728,388
+3.7%
209,010,755
+7.9%
237,688,974
+13.7%
260,735,192
+9.7%
284,438,859
+9.1%
283,460,842
-0.3%
288,703,688
+1.8%
Painex
599,921
1,335,400
1,722,781
2,109,509
2,806,716
2,971,559
3,117,017
3,612,377
Antifectum
78,267
236,095
2,784,600
4,641,000
6,801,970
8,830,361
Boforce
3,746,761
5,415,371
5,805,084
5,973,927
5,892,465
5,677,041
5,450,492
5,211,524
Cardio Plus
54,395
132,877
262,598
1,128,908
2,213,546
2,379,246
2,527,237
Amelin
100,459
453,272
792,689
2,847,646
6,050,690
5,927,785
5,785,972
Luistene
792,082
809,884
849,370
862,965
874,162
865,592
854,265
840,019
Levigra
3,081,647
3,256,348
3,329,083
3,392,969
3,447,102
3,456,634
3,454,149
3,437,622
Motox
3,132,746
3,194,799
3,267,902
3,333,100
3,389,460
3,323,000
3,247,046
3,161,597
Urofax
10,184,174
11,506,631
13,121,299
14,656,943
16,031,314
17,319,133
18,494,398
19,542,476
Lempra
15,842,049
17,835,278
20,270,144
22,571,692
24,615,824
26,519,923
28,245,990
29,773,537
Sertrum
6,079,788
6,508,487
6,592,661
6,134,926
308,165
235,098
198,000
178,000
Etanos
19,045,118
14,412,043
14,969,928
15,357,194
15,556,457
15,473,336
15,106,052
14,695,275
Ingenuine
7,648,800
8,241,071
8,298,498
8,388,611
7,445,570
7,357,656
7,247,147
7,111,783
Quaxter
9,931,942
10,530,576
11,547,840
12,518,273
13,434,624
14,354,760
15,037,877
15,626,758
Kerzan
4,395,027
4,249,614
4,341,065
4,410,342
4,449,052
4,473,859
4,489,319
4,485,710
Taxis
3,076,062
2,388,966
2,004,138
812,698
200,187
180,621
151,872
132,100
Lysine
3,064,476
3,034,439
3,039,912
3,152,348
3,041,396
3,139,524
3,074,175
2,999,090
Cartox
37,604,491
35,648,686
35,852,907
35,516,601
35,135,006
34,303,211
33,444,825
32,492,342
Medecks
12,452,577
13,791,045
14,649,714
15,569,249
16,612,938
17,780,942
17,228,654
16,629,945
Profyle
5,298,672
5,457,992
7,975,915
10,090,957
11,518,323
12,422,929
12,909,360
13,319,751
Page 1/2
Short Description
This is the Sales forecast as supplied by you for this exercise. It is important that this sales forecast is reviewed in combination with your submitted promotional investments as this forms the basis of the sales response analysis performed by the PromoPlanner.
Comment 1
130

4. Sales Forecast 2018 2019 2020 2021 2022 2023 2024 2025 Tramalin
Actual Value GBP
2018
2019
2020
2021
2022
2023
2024
2025 Σ
186,805,152
193,728,388
+3.7%
209,010,755
+7.9%
237,688,974
+13.7%
260,735,192
+9.7%
284,438,859
+9.1%
283,460,842
-0.3%
288,703,688
+1.8%
Tramalin
515,150
4,978,208
10,067,643
12,852,437
4,772,178
Bloodmine
7,821,968
14,185,158
13,777,213
19,026,935
18,900,096
18,714,382
18,286,551
17,805,254
Spinalin
914,709
1,679,806
2,330,562
4,583,405
6,317,770
7,731,433
9,223,106
10,611,733
Neckpain
8,788,185
7,146,107
8,660,476
10,060,694
11,193,711
12,039,000
12,608,275
13,100,990
Inflameless
427,500
888,021
1,153,155
1,364,985
1,613,294
1,882,177
1,986,288
2,077,278
Fungalin
5,860,036
6,693,047
7,440,438
7,951,340
8,156,630
8,018,806
7,855,924
7,667,984
Stomax
6,725,664
15,465,240
22,423,800
23,555,000
23,752,178
Bloodpump
3,296,270
3,407,723
3,704,538
3,848,943
3,986,280
4,114,870
4,232,851
4,328,329
Ferexis
13,720,151
11,957,042
13,126,566
13,005,114
13,514,613
13,901,900
14,081,030
14,194,288
Page 2/2
Short Description
This is the Sales forecast as supplied by you for this exercise. It is important that this sales forecast is reviewed in combination with your submitted promotional investments as this forms the basis of the sales response analysis performed by the PromoPlanner.
Comment 2
130

5. Cost Of Goods
2018
2019
2020
2021
2022
2023
2024
2025
Painex
13%
Antifectum
19%
Boforce 4%
Cardio Plus
Amelin
Luistene 6%
Levigra 8%
Motox
11%
Urofax
17%
Lempra
50%
55%
Sertrum
35%
52%
66%
Etanos
12%
20%
27%
Ingenuine
Quaxter
10%
Kerzan
Taxis 5%
34%
Lysine
Cartox 7%
32%
Medecks
15%
Profyle
21%
Page 1/2
Short Description
As the PromoPlanner optimizes your long term profitability, it is important that the Cost of Goods of your brands is taken into consideration. COGs can vary significantly between different products particularly between those that have patent protection and those that do not. Please ensure that any future expected price changes are taken into consideration in your calculations.
Comment 3
130

6. Cost Of Goods
2018
2019
2020
2021
2022
2023
2024
2025
Tramalin
19%
42%
Bloodmine
26%
Spinalin
14%
Neckpain
18%
24%
28%
Inflameless
22%
Fungalin 5%
Stomax
56%
Bloodpump
Ferexis
Page 2/2
Short Description
As the PromoPlanner optimizes your long term profitability, it is important that the Cost of Goods of your brands is taken into consideration. COGs can vary significantly between different products particularly between those that have patent protection and those that do not. Please ensure that any future expected price changes are taken into consideration in your calculations.
Comment 4
130

7. Initial FTEs
Actual Value GBP
2018
2019
2020
2021
2022
2023
2024
2025 Σ
235
234
-0.5%
236
+0.6%
241
+2.4%
243
+0.8%
246
+1.3%
247
+0.0%
Painex
1.3
2.2
4.3
Antifectum
0.7
2.4
2.6
Boforce
1.7
1.6
2.1
2.3
Cardio Plus
0.3
0.4
Amelin
0.1
Luistene
1.9
Levigra
Motox
4.4
4.6
4.0
Urofax
3.9
Lempra
9.4
9.3
10.8
Sertrum
11.3
12.1
12.0
10.0
Etanos
6.7
Ingenuine
13.5
12.3
12.8
Quaxter
32.4
32.3
31.9
30.5
31.0
33.7
Kerzan
13.9
11.4
Taxis
9.2
7.1
6.3
2.7
Lysine
6.5
10.1
7.9
6.4
Cartox
33.5
28.4
28.6
26.4
28.9
Medecks
7.7
11.5
13.3
Profyle
3.7
4.8
5.1
5.0
Page 1/2
Short Description
These are the FTEs you have submitted that are expected to drive the Sales Forecast. Do make sure that these are annualized FTE numbers. As an example if you have 10 FTEs promoting a brand for half the year, you need to enter 5 FTEs in this table. Please also ensure that all third party or contract sales force personnel are included in this table.
Comment 5
130

8. Initial FTEs
Actual Value GBP
2018
2019
2020
2021
2022
2023
2024
2025 Σ
235
234
-0.5%
236
+0.6%
241
+2.4%
243
+0.8%
246
+1.3%
247
+0.0%
Tramalin
0.9
3.0
3.7
Bloodmine
17.4
16.5
15.9
14.4
13.8
Spinalin
5.6
7.5
7.7
8.4
8.3
7.2
Neckpain
1.3
2.7
3.8
3.9
Inflameless
2.8
3.1
3.4
3.3
Fungalin
2.6
4.1
5.2
6.7
Stomax
0.2
0.8
Bloodpump
9.0
9.5
9.3
13.3
Ferexis
33.2
28.6
28.4
37.1
34.7
31.0
Page 2/2
Short Description
These are the FTEs you have submitted that are expected to drive the Sales Forecast. Do make sure that these are annualized FTE numbers. As an example if you have 10 FTEs promoting a brand for half the year, you need to enter 5 FTEs in this table. Please also ensure that all third party or contract sales force personnel are included in this table.
Comment 6
130

9. Rep Costs 2018 2019 2020 2021 2022 2023 2024 2025 Painex Antifectum
Actual Value GBP
2018
2019
2020
2021
2022
2023
2024
2025
Change
+2.6%
+3.6%
+5.5%
+3.8%
+4.4%
+3.0%
Painex
115,252
118,816
122,380
126,052
129,833
133,728
137,740
141,873
Antifectum
Boforce
Cardio Plus
Amelin
Luistene
Levigra
Motox
Urofax
Lempra
Sertrum
Etanos
Ingenuine
Quaxter
Kerzan
Taxis
Lysine
Cartox
Medecks
Profyle
Page 1/2
Short Description
These Fully Loaded costs will be multiplied by the FTEs you have supplied to determine your sales force investment. They typically increase over time due to inflation. There may be different costs for some brands for example if promoted by highly specialized hospital reps compared to less specialized primary care or contract reps.
Comment 7
130

10. Rep Costs 2018 2019 2020 2021 2022 2023 2024 2025 Tramalin Bloodmine
Actual Value GBP
2018
2019
2020
2021
2022
2023
2024
2025
Change
+2.6%
+3.6%
+5.5%
+3.8%
+4.4%
+3.0%
Tramalin
115,252
118,816
122,380
126,052
129,833
133,728
137,740
141,873
Bloodmine
Spinalin
Neckpain
Inflameless
Fungalin
Stomax
Bloodpump
Ferexis
Page 2/2
Short Description
These Fully Loaded costs will be multiplied by the FTEs you have supplied to determine your sales force investment. They typically increase over time due to inflation. There may be different costs for some brands for example if promoted by highly specialized hospital reps compared to less specialized primary care or contract reps.
Comment 8
130

11. Other Promo Expenditures
Actual Value GBP
2018
2019
2020
2021
2022
2023
2024
2025 Σ
13,445,896
14,225,587
+5.8%
16,159,238
+13.6%
22,510,921
+39.3%
22,004,604
-2.2%
21,598,673
-1.8%
20,388,621
-5.6%
19,208,167
-5.8%
Painex
59,640
89,460
119,280
149,100
178,920
208,740
238,560
Antifectum
752,400
2,143,200
1,748,400
1,470,000
1,375,200
Boforce
166,992
137,172
Cardio Plus
39,459
46,238
49,383
52,527
Amelin
9,689
11,353
12,125
12,897
Luistene
80,514
83,496
92,442
Levigra
172,956
190,848
Motox
279,984
294,624
292,236
Urofax
546,919
547,675
527,814
518,868
575,368
632,271
689,176
Lempra
1,276,145
1,277,909
1,231,566
1,210,692
1,342,525
1,475,300
1,608,077
Sertrum
268,380
200,000
Etanos
559,006
424,845
446,087
459,470
Ingenuine
724,030
730,533
756,102
782,565
Quaxter
913,680
1,013,880
1,073,520
Kerzan
360,104
381,100
408,534
418,673
Taxis
315,192
284,004
293,952
304,236
260,000
220,000
Lysine
425,532
394,197
365,200
336,228
Cartox
1,234,549
1,192,801
1,180,561
1,157,017
Medecks
524,833
506,941
620,257
578,509
584,473
596,401
Profyle
289,851
715,681
Page 1/2
Short Description
This table shoes the non sales-force driven promotional investments you are planning currently. It may include print advertising, e-detailing, web content production, tele-marketing, other digital media and non digital promotional channels. If samples have not been considered as part of your fully loaded rep costs, please ensure the cost of samples is included here if relevant.
Comment 9
130

12. Other Promo Expenditures
Actual Value GBP
2018
2019
2020
2021
2022
2023
2024
2025 Σ
13,445,896
14,225,587
+5.8%
16,159,238
+13.6%
22,510,921
+39.3%
22,004,604
-2.2%
21,598,673
-1.8%
20,388,621
-5.6%
19,208,167
-5.8%
Tramalin
298,200
656,041
834,961
1,073,521
1,431,362
1,100,000
1,000,000
Bloodmine
1,088,799
758,975
736,555
876,500
954,032
1,031,564
1,109,096
Spinalin
544,484
477,121
518,869
Neckpain
506,941
536,761
Inflameless
333,984
241,542
Fungalin
250,489
271,601
282,336
Stomax
600,000
1,200,000
4,800,000
4,200,000
3,600,000
Bloodpump
238,560
256,452
268,679
278,221
Ferexis
2,141,195
1,985,990
2,165,909
3,011,712
3,023,454
2,878,573
1,795,840
711,470
Page 2/2
Short Description
This table shoes the non sales-force driven promotional investments you are planning currently. It may include print advertising, e-detailing, web content production, tele-marketing, other digital media and non digital promotional channels. If samples have not been considered as part of your fully loaded rep costs, please ensure the cost of samples is included here if relevant.
Comment 10
130

13. Strategic Output
These are the product-level insights resulting from the Strategic Analysis section of the PromoPlanner. This step is automatic and fast.

14. Percentages relate to proportion of top 10 brand sales
Base Case Summary I – Sales Forecast
Input Data Visualisation
This slide shows your input data in a graphical form for easy review.
Rank
Brand
5 Years Sales Forecast 1
Cartox
176,456,411 2
Lempra
111,812,861 3
Bloodmine
84,603,784 4
Medecks
78,403,888 5
Etanos
75,768,958 6
Urofax
72,635,320 7
Ferexis
65,505,235 8
Quaxter
62,386,073 9
Neckpain
49,099,988 10
Profyle
47,466,116
Percentages relate to proportion of top 10 brand sales 11
130

15. Base Case Summary II Input Data Visualization
This slide shows your input data in a graphical form for easy review.

16. Total Sales One Year (Butterfly)
Promotional Budget 2019
Sales 2019
5,384,128
Ferexis
11,957,042
4,851,637
Quaxter
10,530,576
4,567,175
Cartox
35,648,686
2,826,373
Bloodmin…
14,185,158
2,394,779
Lempra
17,835,278
2,191,970
Ingenuin…
8,241,071
1,873,325
Medecks
13,791,045
1,723,721
Kerzan
4,249,614
1,706,054
Sertrum
6,508,487
1,594,239
Lysine
3,034,439
1,385,204
Bloodpum…
3,407,723
1,368,241
Spinalin
1,679,806
1,285,998
Profyle
5,457,992
1,220,912
Etanos
14,412,043
1,127,598
Taxis
2,388,966
1,022,939
Urofax
11,506,631
857,564
Neckpain
7,146,107
845,451
Inflamel…
888,021
817,414
Motox
3,194,799
758,747
Fungalin
6,693,047
1-20

17. Total Sales One Year (Butterfly)
Promotional Budget 2019
Sales 2019
600,000
Stomax
440,362
Levigra
3,256,348
357,098
Boforce
5,415,371
309,246
Luistene
809,884
298,200
Tramalin
243,921
Painex
1,335,400
Antifect…
Cardio P…
54,395
Amelin
100,459
21-29

18. Total Sales Five Years (Butterfly)
Promotional Budget
Sales
33,266,670
Ferexis
65,505,235
25,425,681
Quaxter
62,386,073
23,663,541
Cartox
176,456,411
14,636,059
Stomax
44,614,704
14,163,563
Bloodmin…
84,603,784
12,823,977
Lempra
111,812,861
11,599,009
Ingenuin…
39,731,406
10,272,698
Medecks
78,403,888
9,212,389
Kerzan
21,923,932
8,433,611
Spinalin
22,642,976
8,259,608
Sertrum
19,779,337
7,834,679
Bloodpum…
19,062,354
6,886,762
Lysine
15,407,619
6,861,528
Antifect…
7,739,962
6,746,513
Profyle
47,466,116
6,475,762
Etanos
75,768,958
5,470,763
Urofax
72,635,320
5,401,966
Tramalin
28,413,438
4,989,143
Neckpain
49,099,988
4,580,426
Taxis
5,586,610
1-20

19. Total Sales Five Years (Butterfly)
Promotional Budget
Sales
4,477,771
Fungalin
38,260,261
4,186,760
Motox
16,508,261
3,705,994
Inflamel…
6,901,632
2,469,682
Painex
10,945,965
2,438,271
Levigra
16,882,136
1,883,501
Boforce
28,763,888
1,696,302
Luistene
4,261,973
178,138
Cardio P…
3,792,324
60,003
Amelin
10,244,756
21-29

20. Carryover Assessment 2019 2020 2021 2022 2023 2024 2025 Painex
167%
103%
96%
100%
82%
81%
90%
Antifectum
116%
858%
120%
113%
105%
Boforce
128%
97%
93%
88%
86%
85%
84%
Cardio Plus
244%
198%
371%
179%
99%
98%
Amelin
451%
169%
352%
210%
Luistene
77%
79%
76%
74%
73%
Levigra
89%
87%
Motox
83%
80%
Urofax
95%
94%
Lempra
92%
91%
Sertrum 3%
43%
47%
50%
Etanos
66%
Ingenuine
72%
Quaxter
Kerzan
78%
Taxis
61%
64%
27%
16%
53%
51%
Lysine
Cartox
Medecks
Profyle
118%
106%
Page 1/2
Short Description
Carryover is a measure of each products sales momentum. The percentage relates to the amount of sales of the previous years forecast that is expected to CARRYOVER into this year if we assume there to be no promotional investment in the current year.
Comment 17
130

21. Carryover Assessment 2019 2020 2021 2022 2023 2024 2025 Tramalin
678%
161%
106%
28%
81%
Bloodmine
137%
79%
112%
83%
82%
80%
Spinalin
119%
100%
136%
98%
95%
Neckpain
70%
102%
99%
96%
94%
92%
91%
Inflameless
127%
93%
89%
84%
Fungalin
Stomax
162%
117%
88%
85%
Bloodpump
76%
74%
73%
Ferexis
68%
75%
78%
Page 2/2
Short Description
Carryover is a measure of each products sales momentum. The percentage relates to the amount of sales of the previous years forecast that is expected to CARRYOVER into this year if we assume there to be no promotional investment in the current year.
Comment 18
130

22. Promotional Impact Segments
All Products
Future Promotion
Past Promotion
34,012,609
64,462,465
92,431,541
118,888,913
146,018,791
170,054,722
191,374,334
100,423,498
209,819,104
360,752,848
549,704,416
751,437,581
970,324,432
Cumulated Impact of 2019 Promotional Effort (Payback)
Cumulated Impact of Continuous promotion
85%
89%
92%
91%
84%
86%
Carryover 19
130

23. Promotional Impact Segments
Painex
Future Promotion
Past Promotion
334,475
679,895
1,011,282
1,342,441
1,614,466
1,835,892
2,034,951
1,023,578
2,141,405
3,957,118
6,114,635
8,569,032
11,585,718
Cumulated Impact of 2019 Promotional Effort (Payback)
Cumulated Impact of Continuous promotion
167%
103%
96%
100%
82%
81%
90%
Carryover 20
130

24. Promotional Impact Segments
Antifectum
Future Promotion
Past Promotion
78,267
314,362
3,098,962
7,739,962
14,541,932
23,372,293
Cumulated Impact of 2019 Promotional Effort (Payback)
Cumulated Impact of Continuous promotion 0%
116%
858%
120%
113%
105%
Carryover 21
130

25. Promotional Impact Segments
Boforce
Future Promotion
Past Promotion
610,081
1,202,620
1,756,207
2,245,618
2,664,977
3,021,543
3,322,101
1,748,039
3,361,647
5,399,266
7,773,232
10,415,238
13,259,425
Cumulated Impact of 2019 Promotional Effort (Payback)
Cumulated Impact of Continuous promotion
128%
97%
93%
88%
86%
85%
84%
Carryover 22
130

26. Incremental Sales Long Term (Butterfly)
Promotional Budget 2019
Incremental Sales Long-Term 2019
5,384,128
Ferexis
8,164,602
4,851,637
Quaxter
8,626,489
4,567,175
Cartox
18,357,937
2,826,373
Bloodmin…
15,166,848
2,394,779
Lempra
13,091,512
2,191,970
Ingenuin…
5,085,235
1,873,325
Medecks
8,538,505
1,723,721
Kerzan
2,908,609
1,706,054
Sertrum
2,414,750
1,594,239
Lysine
2,350,786
1,385,204
Bloodpum…
2,836,293
1,368,241
Spinalin
3,893,619
1,285,998
Profyle
4,741,499
1,220,912
Etanos
7,189,207
1,127,598
Taxis
668,053
1,022,939
Urofax
7,446,086
857,564
Neckpain
4,697,973
845,451
Inflamel…
1,401,745
817,414
Motox
2,092,725
758,747
Fungalin
3,780,966
1-20

27. Incremental Sales Long Term (Butterfly)
Promotional Budget 2019
Incremental Sales Long-Term 2019
600,000
Stomax
440,362
Levigra
1,865,998
357,098
Boforce
2,482,852
309,246
Luistene
615,311
298,200
Tramalin
243,921
Painex
1,453,842
Antifect…
Cardio P…
1,981,482
Amelin
3,334,291
21-29

28. ROI Long Term 2019 (Butterfly)
Promotional Budget 2019
ROI 2019
5,384,128
Ferexis
71%
4,851,637
Quaxter
161%
4,567,175
Cartox
350%
2,826,373
Bloodmin…
360%
2,394,779
Lempra
539%
2,191,970
Ingenuin…
225%
1,873,325
Medecks
390%
1,723,721
Kerzan
160%
1,706,054
Sertrum
126%
1,594,239
Lysine
126%
1,385,204
Bloodpum…
152%
1,368,241
Spinalin
230%
1,285,998
Profyle
342%
1,220,912
Etanos
493%
1,127,598
Taxis
77%
1,022,939
Urofax
621%
857,564
Neckpain
435%
845,451
Inflamel…
134%
817,414
Motox
231%
758,747
Fungalin
508%
1-20

29. ROI Long Term 2019 (Butterfly)
Promotional Budget 2019
ROI 2019
600,000
Stomax 0%
440,362
Levigra
396%
357,098
Boforce
716%
309,246
Luistene
194%
298,200
Tramalin 0%
243,921
Painex
576%
Antifect… 0%
Cardio P… 0%
Amelin 0%
21-29

30. Promotional ROI 2019 2020 2021 Painex Antifectum Boforce Cardio Plus
Portfolio Average:
285%
279%
272%
Painex
576%
467%
381%
Antifectum
316%
232%
Boforce
716%
640%
597%
Cardio Plus
Amelin
4,775%
Luistene
194%
200%
174%
Levigra
396%
385%
358%
Motox
231%
227%
Urofax
621%
635%
636%
Lempra
539%
516%
469%
Sertrum
126%
89%
47%
Etanos
493%
485%
448%
Ingenuine
225%
206%
201%
Quaxter
161%
170%
178%
Kerzan
160%
159%
156%
Taxis
77%
51%
30%
Lysine
128%
146%
Cartox
350%
327%
303%
Medecks
390%
377%
Profyle
342%
446%
420%
Page 1/2
Short Description
The ROI Assessment is shown for the entire Portfolio and for each product.
Comment 53
130

31. Promotional ROI 2019 2020 2021 Tramalin Bloodmine Spinalin Neckpain
Portfolio Average:
285%
279%
272%
Tramalin
1,778%
626%
Bloodmine
360%
304%
328%
Spinalin
230%
256%
329%
Neckpain
435%
472%
462%
Inflameless
134%
131%
148%
Fungalin
508%
484%
454%
Stomax
467%
Bloodpump
152%
156%
Ferexis
71%
75%
60%
Page 2/2
Short Description
The ROI Assessment is shown for the entire Portfolio and for each product.
Comment 54
130

32. FTE Base Plan Optimized Alert Level 2018 2019 2020 2021 2022 2023 2019Σ
235
234
236
241
243
246
218
215
Painex
1.30
2.2
4.3
3.8
3.5
4.0
Antifectum
0.70
2.4
2.6
0.59
3.6
Boforce
1.70
1.60
2.1
2.3
4.7
4.2
4.4
Cardio Plus
0.30
0.40
1.79
Amelin
0.10
2.8
1.90
Luistene
1.25
1.19
1.31
Levigra
Motox
4.6
3.4
3.3
3.2
Urofax
3.9
12.0
Lempra
9.4
9.3
10.8
16.0
15.3
Sertrum
11.3
12.1
10.0
2.0
1.07
0.26
0.22
Etanos
6.7
11.9
11.0
11.1
Ingenuine
13.5
12.3
12.8
9.0
8.0
7.7
8.2
Quaxter 32 31 34
19.1 20 21 22
Kerzan
13.9
11.4
5.9
5.8
6.0
6.1
Taxis
9.2
7.1
6.3
2.7
0.98
0.67
0.36
0.17
0.20
Lysine
6.5
10.1
7.9
6.4
Cartox 28 29 26 30 27
Medecks
11.5
13.3
17.6
16.4
17.2
16.1
Profyle
3.7
4.8
5.1
5.0
7.6
10.4
8.6
7.8
Page 1/2
2019
Under
Over
Description
This table compares the Base Case FTE plan you have submitted with the PromoPlanner recommendation. The coloured bars are a representation of the extent to which your current plan is over or under invested. Bars pointing to the left indicate your current plan is under-resourcing the brand. Bars pointing to the right are over resourcing your brand. The colours and length represent the severity of the situation. Red bars suggest action needs to be taken now, yellow bars suggest the situation needs to be watched closely, green bars suggest the plan is fine. The bars only comment on the first year of optimisation. 55
130

33. FTE Base Plan Optimized Alert Level 2018 2019 2020 2021 2022 2023 2019Σ
235
234
236
241
243
246
218
215
Tramalin
0.90
3.0
3.7
3.9
2.2
4.1
2.9
Bloodmine
17.4
16.5
15.9
14.4
13.8 24
18.1 21
15.6
14.8
Spinalin
5.6
7.5
7.7
8.4
8.3
7.2
9.3
10.5
11.2
10.1
Neckpain
1.30
2.7
3.8
5.3
8.1
7.4
7.0
Inflameless
2.8
3.1
3.4
3.3
1.48
1.91
2.1
Fungalin
2.6
5.2
6.7
8.2
8.0
8.5
Stomax
0.20
0.80
0.24
0.74
0.76
Bloodpump
9.0
9.5
13.3
5.4
6.4
Ferexis 33 29 28 37 35 31
7.3
7.8
Page 2/2
2019
Under
Over
Description
This table compares the Base Case FTE plan you have submitted with the PromoPlanner recommendation. The coloured bars are a representation of the extent to which your current plan is over or under invested. Bars pointing to the left indicate your current plan is under-resourcing the brand. Bars pointing to the right are over resourcing your brand. The colours and length represent the severity of the situation. Red bars suggest action needs to be taken now, yellow bars suggest the situation needs to be watched closely, green bars suggest the plan is fine. The bars only comment on the first year of optimisation. 56
130

34. Operational Output
These are the customer/product/team/marketing channel insights resulting from the Operational & Tactical Analysis section of the PromoPlanner.
It will require additional input on your customers and your market landscape, so the process takes a little longer. But what you get is really worth it.

35. Value Split This is line 2 This is line 3 This is line 4 Description
Comment 57
130

36. Value Split Painex Antifectum Boforce Cardio Plus Amelin Luistene
GPs
Retail Pharmacies
Pediatrician
Gynecologist - Obstetri..
Internal Medicine
Surgery
Orthopedics
Psychiatry
Otolaryngology
Cardiologists
Dermatology
Urology
Neurologists
Pulmonologist
Oncology Nurse
Oncologist
Endocrinologist
Nefrologist
Rheumatologist
Mastologists
Painex
21% 9% 4%
Antifectum
30% 1% 5%
10%
Boforce 8%
49%
19%
Cardio Plus
24%
57%
Amelin
25%
51%
Luistene
12%
Levigra
23%
20%
Motox
Urofax
29%
38%
Lempra
48%
Sertrum
Etanos
40%
Ingenuine
Value Split
Products 1 to 13 58
130

37. Value Split Painex Antifectum Boforce Cardio Plus Amelin Luistene
Neurosurgery
Trauma Specialist
Hematologist
Anesthesiologists
Infect. Spec.
Allergist
Emergency Spec.
Geriatrician
Patients
Institutions (Promotion..
Patient Advocacy Groups
Nurses
Painex
26% 4% 8%
Antifectum
10% 5%
Boforce
Cardio Plus
Amelin
Luistene
19%
Levigra
Motox
Urofax
Lempra
Sertrum
48%
Etanos
25%
Ingenuine
80%
Value Split
Products 1 to 13 59
130

38. Value Split Quaxter Kerzan Taxis Lysine Cartox Medecks Profyle
GPs
Retail Pharmacies
Pediatrician
Gynecologist - Obstetri..
Internal Medicine
Surgery
Orthopedics
Psychiatry
Otolaryngology
Cardiologists
Dermatology
Urology
Neurologists
Pulmonologist
Oncology Nurse
Oncologist
Endocrinologist
Nefrologist
Rheumatologist
Mastologists
Quaxter
49% 4%
34%
Kerzan
10% 1%
78%
Taxis
15%
73%
Lysine
29%
68%
Cartox 5%
Medecks
21%
Profyle
Tramalin
76%
Bloodmine 2%
19%
Spinalin
95%
Neckpain
38%
Inflameless
67%
Fungalin
Value Split
Products 14 to 26 60
130

39. Value Split Quaxter Kerzan Taxis Lysine Cartox Medecks Profyle
Neurosurgery
Trauma Specialist
Hematologist
Anesthesiologists
Infect. Spec.
Allergist
Emergency Spec.
Geriatrician
Patients
Institutions (Promotion..
Patient Advocacy Groups
Nurses
Quaxter 5%
Kerzan
10%
Taxis
Lysine
Cartox
Medecks
45%
Profyle
95%
Tramalin
Bloodmine
67%
Spinalin
Neckpain
38%
19%
Inflameless
Fungalin
Value Split
Products 14 to 26 61
130

40. Value Split Stomax Bloodpump Ferexis 19% 1% 10% 57% 38% 29% GPs
Retail Pharmacies
Pediatrician
Gynecologist - Obstetri..
Internal Medicine
Surgery
Orthopedics
Psychiatry
Otolaryngology
Cardiologists
Dermatology
Urology
Neurologists
Pulmonologist
Oncology Nurse
Oncologist
Endocrinologist
Nefrologist
Rheumatologist
Mastologists
Stomax
19% 1%
10%
57%
Bloodpump
38%
Ferexis
29%
Value Split
Products 27 to 29 62
130

41. Value Split Stomax Bloodpump Ferexis 38% 10% 19% Neurosurgery
Trauma Specialist
Hematologist
Anesthesiologists
Infect. Spec.
Allergist
Emergency Spec.
Geriatrician
Patients
Institutions (Promotion..
Patient Advocacy Groups
Nurses
Stomax
Bloodpump
38%
10%
Ferexis
19%
Value Split
Products 27 to 29 63
130

42. 2018 Long Term Business impact by customer type
This chart shows where the impactable business* will be coming from over the next 5 years. It is often very interesting to see how this compares with your promotional investment.
* Impactable business is defined as the Net Long term Incremental Sales as determined by the PromoPlanner Sales Response analysis.
14% GP
84% Specialist
2% Retail
0% Patient
0% Institution 64
130

43. Description S Painex Antifectum Boforce Cardio Plus Amelin Luistene
29 %
17 %
10 %
0 %
4 %
1 %
2 %
7 %
3 %
19 %
16 %
6 %
Products 1 to 20
Base Plan
Optimized
Alert Level
GPs
Retail Pharmacies
Pediatrician
Gynecologist - Obstetrician
Internal Medicine
Surgery
Orthopedics
Psychiatry
Otolaryngology
Cardiologists
Dermatology
Urology
Neurologists
Pulmonologist
Oncology Nurse
Oncologist
Endocrinologist
Nefrologist
Rheumatologist
Mastologists S
234
145
Under
Over 28
1.07
3.8 23
4.5
5.5
4.1
5.3
10.8
5.0
9.9
8.1
1.99
Painex
1.30
1.54
0.53
0.26
0.29
Antifectum
Boforce
1.60
3.7
0.34
2.8
0.60
Cardio Plus
4.9
1.08
Amelin
17.2
2.6
Luistene
1.90
0.10
0.12
Levigra
2.1
1.09
0.73
0.25
Motox
4.4
0.58
0.50
Urofax
4.0
12.3
2.2
5.6
Lempra
9.4
18.2
6.1
6.7
Sertrum
12.1
1.66
Etanos
10.4
3.6
Ingenuine
5.7
Quaxter 32
11.3
6.8
0.45
Kerzan
0.48
Taxis
7.1
Lysine
10.1
1.53
0.67
0.86
Cartox
11.9
Medecks
11.5
2.7
5.1
Profyle
4.8
Description
This report extends the information on the previous FTE allocation report to the customer dimension. To achieve this result the PromoPlanner has used the information you supplied during the Customer Landscape exercise. This may result in a slightly different total brand FTE recommendation than on the earlier report, usually a little smaller. This result is more accurate. 65
130

44. Description S Painex Antifectum Boforce Cardio Plus Amelin Luistene
1 %
2 %
0 %
5 %
11 %
Products 1 to 20
Base Plan
Optimized
Alert Level
Neurosurgery
Trauma Specialist
Hematologist
Anesthesiologists
Infect. Spec.
Allergist
Emergency Spec.
Geriatrician
Patients
Institutions (Promotion Not Required)
Patient Advocacy Groups
Nurses S
234
145
Under
Over
7.8
6.6
15.3
Painex
1.30
1.54
0.46
Antifectum
Boforce
1.60
3.7
Cardio Plus
4.9
Amelin
17.2
Luistene
1.90
0.34
Levigra
2.1
1.09
Motox
4.4
1.08
Urofax
4.0
12.3
Lempra
9.4
18.2
Sertrum
12.1
1.66
Etanos
6.7
10.4
1.88
Ingenuine
5.7
Quaxter 32
11.3
Kerzan
0.48
Taxis
7.1
Lysine
10.1
1.53
Cartox 28
11.9
Medecks
11.5
4.1
Profyle
4.8
5.6
Description
This report extends the information on the previous FTE allocation report to the customer dimension. To achieve this result the PromoPlanner has used the information you supplied during the Customer Landscape exercise. This may result in a slightly different total brand FTE recommendation than on the earlier report, usually a little smaller. This result is more accurate. 66
130

45. Description S Tramalin Bloodmine Spinalin Neckpain Inflameless
29 %
17 %
10 %
0 %
4 %
1 %
2 %
7 %
3 %
19 %
16 %
6 %
Products 21 to 29
Base Plan
Optimized
Alert Level
GPs
Retail Pharmacies
Pediatrician
Gynecologist - Obstetrician
Internal Medicine
Surgery
Orthopedics
Psychiatry
Otolaryngology
Cardiologists
Dermatology
Urology
Neurologists
Pulmonologist
Oncology Nurse
Oncologist
Endocrinologist
Nefrologist
Rheumatologist
Mastologists S
234
145
Under
Over 28
1.07
3.8 23
4.5
5.5
4.1
5.3
10.8
5.0
9.9
8.1
1.99
Tramalin
Bloodmine
17.4
10.1
2.1
Spinalin
7.5
Neckpain
2.7
2.5
Inflameless
3.1
0.38
Fungalin
Stomax
Bloodpump
9.5
2.4
0.18
1.34
Ferexis 29
1.94
Description
This report extends the information on the previous FTE allocation report to the customer dimension. To achieve this result the PromoPlanner has used the information you supplied during the Customer Landscape exercise. This may result in a slightly different total brand FTE recommendation than on the earlier report, usually a little smaller. This result is more accurate. 67
130

46. Description S Tramalin Bloodmine Spinalin Neckpain Inflameless
1 %
2 %
0 %
5 %
11 %
Products 21 to 29
Base Plan
Optimized
Alert Level
Neurosurgery
Trauma Specialist
Hematologist
Anesthesiologists
Infect. Spec.
Allergist
Emergency Spec.
Geriatrician
Patients
Institutions (Promotion Not Required)
Patient Advocacy Groups
Nurses S
234
145
Under
Over
7.8
6.6
15.3
Tramalin
Bloodmine
17.4
10.1
6.0
1.96
Spinalin
7.5
5.0
Neckpain
2.7
3.8
1.28
Inflameless
3.1
0.38
Fungalin
4.1
Stomax
Bloodpump
9.5
2.4
0.58
0.33
Ferexis 29
1.94
Description
This report extends the information on the previous FTE allocation report to the customer dimension. To achieve this result the PromoPlanner has used the information you supplied during the Customer Landscape exercise. This may result in a slightly different total brand FTE recommendation than on the earlier report, usually a little smaller. This result is more accurate. 68
130

47. Plan of Action Short Description Comment
Internal Medicine / Team Trauma Team
Short Description
This chart shows the promotional investment curve that you are able to deploy profitably on the named Customer Specialty taking into account the products being carried by the selected Sales Force team. It also shows the sales force investment annual calls you have decided to deploy(Reach & Frequency), together with any non sales force driven promotional channel investments you have chosen to deploy.
Comment
Enter Comment here. 72
130

48. Plan of Action Short Description Comment
Cardiologists / Team CardioVascular Team
Short Description
This chart shows the promotional investment curve that you are able to deploy profitably on the named Customer Specialty taking into account the products being carried by the selected Sales Force team. It also shows the sales force investment annual calls you have decided to deploy(Reach & Frequency), together with any non sales force driven promotional channel investments you have chosen to deploy.
Comment
Enter Comment here. 76
130

49. Plan of Action Short Description Comment Dermatology / Team GP Team
This chart shows the promotional investment curve that you are able to deploy profitably on the named Customer Specialty taking into account the products being carried by the selected Sales Force team. It also shows the sales force investment annual calls you have decided to deploy(Reach & Frequency), together with any non sales force driven promotional channel investments you have chosen to deploy.
Comment
Enter Comment here. 77
130

50. Promo Plan by Customer Short Description Comment Cardiologists
This is your optimized Promotional Plan for the Customer Specialty.
Comment
Enter Comment here. 95
130

51. Promo Plan by Customer Short Description Comment Neurologists
This is your optimized Promotional Plan for the Customer Specialty.
Comment
Enter Comment here. 98
130

52. Plan of Action Short Description Comment
Retail Pharmacies / Team Retail Pharmacy Team
Short Description
This chart shows the promotional investment curve that you are able to deploy profitably on the named Customer Specialty taking into account the products being carried by the selected Sales Force team. It also shows the sales force investment annual calls you have decided to deploy(Reach & Frequency), together with any non sales force driven promotional channel investments you have chosen to deploy.
Comment
Enter Comment here. 70
130

53. Plan Summary – By Product
2019 Current State of Plan from the Specialty Summary screen output
Page 1/3
Products
FTEs
Promo Investment
Non FTEs
Total
Sales
Incremental
Sales
(Sales Response
Short Term Gross)
Long Term Gross)
Profit Response
Long Term
Promo. ROI
Totals
142
16,882,786
11,065,109
27,947,895
159,715,779
54,333,921
324,729,186
63,109,026
326%
Painex
1.54
183,308
57,707
241,015
1,000,925
432,684
1,880,722
588,623
344%
Antifectum 0%
Boforce
3.0
360,832
126,810
487,642
4,805,290
822,553
3,347,554
1,229,091
352%
Cardio Plus
5.5
652,091
848,435
30,906,486
1,280,117
296%
Amelin
17.2
2,038,716
2,680,086
88,953,567
4,386,249
315%
Luistene
0.34
40,352
50,072
90,423
610,276
173,243
534,040
223,259
347%
Levigra
1.11
131,693
119,275
250,968
2,756,968
447,751
1,673,079
601,457
340%
Motox
1.08
128,264
283,391
411,655
2,597,526
780,369
2,734,258
991,133
341%
Urofax
11.4
1,351,140
526,795
1,877,935
9,919,849
3,263,811
15,315,656
3,899,655
308%
Lempra
16.7
1,985,519
739,181
2,724,700
14,837,362
4,564,576
19,932,911
7,237,184
366%
112
130

54. Plan Summary – By Product
2019 Current State of Plan from the Specialty Summary screen output
Page 2/3
Products
FTEs
Promo Investment
Non FTEs
Total
Sales
Incremental
Sales
(Sales Response
Short Term Gross)
Long Term Gross)
Profit Response
Long Term
Promo. ROI
Totals
142
16,882,786
11,065,109
27,947,895
159,715,779
54,333,921
324,729,186
63,109,026
326%
Sertrum
1.66
196,994
258,148
455,142
5,145,007
1,734,978
3,072,680
1,191,177
362%
Etanos
10.4
1,240,323
430,156
1,670,478
12,568,180
3,000,561
11,699,166
3,782,084
Ingenuine
5.7
681,697
739,665
1,421,362
6,693,440
2,637,419
8,666,083
3,475,781
345%
Quaxter
11.3
1,342,296
533,167
1,875,464
8,198,461
3,344,776
12,372,321
4,197,752
324%
Kerzan
0.48
56,626
374,288
430,914
3,380,943
827,104
2,769,431
1,160,416
369%
Taxis
278,927
1,891,768
639,905
859,801
442,033
258%
Lysine
1.36
161,563
387,151
548,714
2,326,205
1,043,452
3,463,451
1,191,897
317%
Cartox
11.9
1,414,897
301,322
1,716,219
30,618,399
3,701,517
13,508,617
6,299,706
467%
Medecks
1,418,172
513,278
1,931,450
11,727,004
3,626,509
15,002,107
4,761,786
347%
Profyle
5.6
663,661
144,478
808,139
4,498,969
1,729,555
8,551,081
2,759,838
442%
113
130

55. Plan Summary – By Product
2019 Current State of Plan from the Specialty Summary screen output
Page 3/3
Products
FTEs
Promo Investment
Non FTEs
Total
Sales
Incremental
Sales
(Sales Response
Short Term Gross)
Long Term Gross)
Profit Response
Long Term
Promo. ROI
Totals
142
16,882,786
11,065,109
27,947,895
159,715,779
54,333,921
324,729,186
63,109,026
326%
Tramalin
286,831
354,113
11,890,093
-215,119
25%
Bloodmine
10.1
1,202,397
739,526
1,941,923
10,752,891
4,365,911
19,292,527
5,695,305
393%
Spinalin
5.0
591,317
458,931
1,050,248
1,089,345
1,633,132
10,769,201
2,335,970
322%
Neckpain
3.8
451,858
523,006
974,865
6,140,476
1,883,939
8,801,132
2,134,618
319%
Inflameless
0.38
45,527
504,457
544,539
832,826
3,398,751
592,342
217%
Fungalin
5,756,481 0%
Stomax
577,125
1,311,648
-432,838
Bloodpump
2.6
313,149
246,675
559,824
2,491,610
1,387,231
4,294,878
1,359,092
343%
Ferexis
1.94
230,393
1,910,274
2,140,667
9,363,865
6,265,835
19,727,945
1,940,417
191%
114
130

56. Above/Below Recommended
Plan Summary – By Specialty
2019 Current State of Plan from the Specialty Summary screen output
Page 1/4
Products
FTEs
Promo Investment
Non FTEs
Total
Above/Below Recommended
Incremental
Sales
(Sales Response
Short Term Gross)
Long Term Gross)
Profit Response
Long Term
Promo. ROI
Totals
142
16,882,786
11,065,109
27,947,895
-8,621,124
54,333,921
324,729,186
63,109,026
326%
GPs 28
3,308,473
1,728,200
5,036,673
-176,985
9,389,563
54,458,428
9,022,453
179%
Retail Pharmacies
1.07
127,105
221,140
348,245
-265,793
696,931
2,734,769
831,354
239%
Pediatrician
3.8
450,647
393,202
843,849
-97,291
1,773,982
23,115,858
1,677,202
199%
Gynecologist - Obstetrician
918,741
-158,200
2,410,217
7,427,477
1,378,277
150%
Internal Medicine
19.3
2,292,307
1,352,801
3,645,107
-253,190
6,721,186
26,129,182
7,480,567
205%
Surgery
4.5
531,264
169,839
701,103
40,274
1,215,875
4,683,389
1,422,821
203%
Orthopedics
5.5
649,527
225,917
875,444
-46,068
1,547,602
5,949,469
1,875,288
214%
Psychiatry
354,113
14,894
815,491
10,343,374
220,933
62%
Otolaryngology
4.1
486,518
344,212
830,730
-54,675
1,478,215
5,467,914
1,848,255
222%
Cardiologists
6.1
721,987
104,895
826,882
49,153
1,390,686
27,021,861
1,704,782
206%
115
130

57. Above/Below Recommended
Plan Summary – By Specialty
2019 Current State of Plan from the Specialty Summary screen output
Page 2/4
Products
FTEs
Promo Investment
Non FTEs
Total
Above/Below Recommended
Incremental
Sales
(Sales Response
Short Term Gross)
Long Term Gross)
Profit Response
Long Term
Promo. ROI
Totals
142
16,882,786
11,065,109
27,947,895
-8,621,124
54,333,921
324,729,186
63,109,026
326%
Dermatology
10.8
1,287,979
-34,306
1,685,041
55,927,479
2,552,492
198%
Urology
4.5
535,551
245,332
780,883
-137,476
1,425,864
6,618,069
1,889,870
242%
Neurologists
5.0
591,317
599,372
1,190,688
-133,643
1,910,668
11,650,299
2,726,400
229%
Pulmonologist
41,323
-995
94,801
127,378
65,486
158%
Oncology Nurse
85,863
-202,661
194,046
562,436
274,931
320%
Oncologist
9.9
1,178,907
395,130
1,574,037
-2,822,565
3,566,178
11,927,747
5,832,621
371%
Endocrinologist
8.1
964,541
472,970
1,437,511
-1,217,466
2,663,018
10,414,917
4,013,949
279%
Nefrologist
1.99
235,990
110,344
346,334
-115,265
599,697
2,305,986
773,541
223%
Rheumatologist
527,706
-282,695
963,393
3,721,203
1,020,548
193%
Mastologists 0%
116
130

58. Above/Below Recommended
Plan Summary – By Specialty
2019 Current State of Plan from the Specialty Summary screen output
Page 3/4
Products
FTEs
Promo Investment
Non FTEs
Total
Above/Below Recommended
Incremental
Sales
(Sales Response
Short Term Gross)
Long Term Gross)
Profit Response
Long Term
Promo. ROI
Totals
142
16,882,786
11,065,109
27,947,895
-8,621,124
54,333,921
324,729,186
63,109,026
326%
Neurosurgery 0%
Trauma Specialist
7.8
921,290
607,301
1,528,591
-702,275
2,975,706
12,560,693
3,997,423
262%
Hematologist
6.6
784,738
602,170
1,386,908
-1,136,405
3,180,101
13,489,123
4,047,790
292%
Anesthesiologists
3,824
-16,191
8,646
37,581
16,072
420%
Infect. Spec.
36,967
-52,268
73,337
245,556
107,045
290%
Allergist
Emergency Spec.
101,985
-175,114
215,381
1,006,187
288,264
283%
Geriatrician
15.3
1,814,644
1,350,019
3,164,663
-516,109
7,191,437
26,269,869
7,818,926
247%
Patients
22,574
-50,495
47,815
166,568
73,892
327%
Institutions (Promotion Not Required)
49,173
-77,313
99,046
366,371
147,843
301%
117
130

59. Above/Below Recommended
Plan Summary – By Specialty
2019 Current State of Plan from the Specialty Summary screen output
Page 4/4
Products
FTEs
Promo Investment
Non FTEs
Total
Above/Below Recommended
Incremental
Sales
(Sales Response
Short Term Gross)
Long Term Gross)
Profit Response
Long Term
Promo. ROI
Totals
142
16,882,786
11,065,109
27,947,895
-8,621,124
54,333,921
324,729,186
63,109,026
326%
Patient Advocacy Groups 0%
Nurses
118
130

60. Team Structure (Summary)
Comparison of Base Case Team Structure vs Planned Team Structure
Page 1/1
Base Case
Plan
Team
FTEs
Calls Made
Calls Planned
Totals
234
142
GP Team 72 39
Geriatrican Team
20.0 24
Endocrine Team
8.1
18.1
CardioVascular Team
17.6
12.7
Trauma Team 37
12.8
Pain Team
17.7
9.9
7692
Oncology Team
5.9
11.9
7168.8
Paediatrican Team
12.3
7.9
Psychiatry/Neurology Team
11.7
5.0
3252.8
Retail Pharmacy Team 31
1.07
883.2
119
130

61. Customers Speciality Visited
Team Structure (Detail)
Comparison of Base Case Team Structure vs Planned Team Structure
GP Team
Page 1/2
Customers Speciality Visited
Base Case
Plan
Planned Team Bag
FTEs
Calls Made
Customer Weighting
Calls Planned
Products Carried
Product Weighting
Team Totals 72
100% 39
GPs 42
59% 28
72%
Amelin
35%
Dermatology
2.4 3%
10.8
8949.6
28%
Quaxter
17%
Pediatrician
15.4
21%
Lempra
14%
Urology
9.7
13%
Medecks 7%
Allergist
1.29
1062.2 2%
Neckpain
Gynecologist - Obstetrician
1.05
868.56 1%
Urofax 6%
Rheumatologist
0.08
62.04 0%
Ferexis 5%
Nefrologist
0.05
41.36
Cardio Plus
Levigra
Painex
Kerzan
Inflameless
120
130

62. Customers Speciality Visited
Team Structure (Detail)
Comparison of Base Case Team Structure vs Planned Team Structure
CardioVascular Team
Page 1/1
Customers Speciality Visited
Base Case
Plan
Planned Team Bag
FTEs
Calls Made
Customer Weighting
Calls Planned
Products Carried
Product Weighting
Team Totals
17.6
100%
12.7
Hematologist
1.85
11%
6.6
5112
52%
Bloodmine
47%
Cardiologists
11.9
68%
6.1
48%
Cardio Plus
35%
GPs
1.38 8%
Bloodpump
17%
Internal Medicine
0.97
748.24 6%
Levigra 1%
Neurologists
0.51
398.56 3%
Geriatrician
392.92
Endocrinologist
0.21
165.44
Rheumatologist
0.11
82.72
Surgery
0.05
41.36 0%
Psychiatry
39.48
Orthopedics
0.03
20.68
124
130

63. Customers Speciality Visited
Team Structure (Detail)
Comparison of Base Case Team Structure vs Planned Team Structure
Oncology Team
Page 1/1
Customers Speciality Visited
Base Case
Plan
Planned Team Bag
FTEs
Calls Made
Customer Weighting
Calls Planned
Products Carried
Product Weighting
Team Totals
5.9
100%
11.9
7168.8
Oncologist
1.89
32%
9.9
83%
Cartox
Nefrologist
1.99
17%
Pulmonologist
1.73
1043.4
29%
Oncology Nurse
1.00
603.48
GPs
0.63
377.88
11%
Internal Medicine
0.38
227.48 6%
Hematologist
0.27
165.44 5%
127
130

64. Customers Speciality Visited
Team Structure (Detail)
Comparison of Base Case Team Structure vs Planned Team Structure
Retail Pharmacy Team
Page 1/1
Customers Speciality Visited
Base Case
Plan
Planned Team Bag
FTEs
Calls Made
Customer Weighting
Calls Planned
Products Carried
Product Weighting
Team Totals 31
100%
1.07
883.2
Retail Pharmacies 30
97%
Quaxter
42%
Rheumatologist
0.36
293.28 1%
Painex
24%
Surgery
0.23
186.12
Levigra
23%
Pulmonologist
0.20
165.44
Luistene
11%
Gynecologist - Obstetrician
0.13
103.4 0%
Otolaryngology
0.05
41.36
Neurologists
Pediatrician
0.03
20.68
130